Thus, the antitumor effect of mOVA2 immunization is due to its capacity to instigate CD8 T cell responses against a tumor-specific antigen, as evident in ELISPOT and pentamer analyses (Fig. 5a–c). The gene discussed is CD8A; the disease is neoplasm.